The drug, odanacatib, limits risk of osteoporotic fractures. However, a late-stage study found postmenopausal women were at an increased risk of stroke when taking the drug. Merck said Friday the findings do not support additional development or regulatory approval.
More articles about supply chain:
Mylan coupled executive pay with high profit targets: 7 things to know
Sunovion Pharmaceuticals to acquire Cynapsus Therapeutics for $624M
Roche seeks FDA approval for additional use of cancer drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.